Abbott, St. Jude Medical grow cardiovascular products alliance
Building upon an agreement that began in 2008, Abbott Laboratories (NYSE: ABT; Abbott Park, IL) and St. Jude Medical (NYSE: STJ; St. Paul, MN) have formed Choice Alliance, a multi-year joint initiative that provides mutual US customers access to a portfolio of interventional cardiology, cardiac rhythm management, electrophysiology, and intravascular imaging and diagnostic technologies.
The alliance includes Abbott's coronary and endovascular product portfolios, including its Xience everolimus eluting coronary stents, and St. Jude Medical's portfolio of electrophysiology, cardiac rhythm management, and cardiology technologies, including ablation catheters, pacemakers, implantable cardioverter defibrillators (ICDs), leads, fractional flow reserve (FFR) lesion assessment technology, and optical coherence tomography (OCT) imaging products. Under the terms of the alliance, the two companies will jointly promote each other's product offerings when developing contract solutions with hospital customers in the United States, enabling both companies to present a combined comprehensive cardiovascular product portfolio. In addition, a separate distribution agreement between the two companies grants Abbott the rights to distribute St. Jude Medical's Ilumien PCI optimization system, which integrates FFR and OCT, as well as the RadiAnalyzer Xpress measurement system, in the United States.
-----
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!